TD Cowen Downgrades 10x Genomics to Hold, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Dan Brennan downgraded 10x Genomics (TXG) from Buy to Hold and reduced the price target from $57 to $32, indicating a more cautious outlook on the company's stock.
May 01, 2024 | 4:27 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TD Cowen's downgrade of 10x Genomics to Hold and the significant reduction in price target could lead to short-term bearish sentiment among investors.
Analyst ratings and price target adjustments are critical factors that influence investor sentiment and stock prices in the short term. The downgrade from Buy to Hold suggests a less optimistic view on the company's future performance, and the significant reduction in the price target from $57 to $32 may lead to decreased investor confidence and a potential decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100